

May 4, 2025

### Q4FY25 Result Update

🗹 Change in Estimates | 🗹 Target | 🔳 Reco

### **Change in Estimates**

	Cu	rrent	Pre	vious
	FY26E	FY27E	FY26E	FY27E
Rating	ACCU	MULATE	ACCU	MULATE
Target Price		718	(	672
Sales (Rs. m)	1,22,685	1,35,517	1,21,204	1,33,715
% Chng.	1.2	1.3		
EBITDA (Rs. m)	23,396	27,062	23,802	26,217
% Chng.	(1.7)	3.2		
EPS (Rs.)	13.4	15.3	13.4	14.6
% Chng.	(0.6)	4.5		

### Key Financials - Consolidated

FY24	FY25	FY26E	FY27E
96,530	1,08,310	1,22,685	1,35,517
20,260	21,390	23,396	27,062
21.0	19.7	19.1	20.0
14,290	15,841	17,228	19,699
11.1	12.3	13.4	15.3
9.8	10.9	8.8	14.3
9.5	10.5	10.5	12.3
1.4	1.5	1.5	1.8
37.5	40.6	41.4	43.5
44.0	45.8	47.4	51.0
9.2	8.2	7.2	6.5
44.1	41.3	37.6	32.5
63.1	56.9	52.3	45.7
23.5	22.7	20.8	19.1
	96,530 20,260 21.0 14,290 11.1 9.8 9.5 1.4 37.5 44.0 9.2 44.1 63.1	96,530         1,08,310           20,260         21,390           21.0         19.7           14,290         15,841           11.1         12.3           9.8         10.9           9.5         10.5           1.4         1.5           37.5         40.6           44.0         45.8           9.2         8.2           44.1         41.3           63.1         56.9	96,530         1,08,310         1,22,685           20,260         21,390         23,396           21.0         19.7         19.1           14,290         15,841         17,228           11.1         12.3         13.4           9.8         10.9         8.8           9.5         10.5         10.5           1.4         1.5         1.5           37.5         40.6         41.4           44.0         45.8         47.4           9.2         8.2         7.2           44.1         41.3         37.6           63.1         56.9         52.3

Key Data	MRCO.BO   MRCO IN
52-W High / Low	Rs.737 / Rs.510
Sensex / Nifty	80,502 / 24,347
Market Cap	Rs.905bn/ \$ 10,703m
Shares Outstanding	1,295m
3M Avg. Daily Value	Rs.1393.47m

### Shareholding Pattern (%)

Promoter's	59.12
Foreign	22.08
Domestic Institution	14.23
Public & Others	4.53
Promoter Pledge (Rs bn)	0.13

### Stock Performance (%)

1M	6M	12M
6.4	8.1	34.9
1.3	7.1	25.0
		6.4 8.1

### **Amnish Aggarwal**

amnishaggarwal@plindia.com | 91-22-66322233

Hasti Savla

hastisavla@plindia.com | 91-22-66322531

Vishwa Solanki

vishwasolanki@plindia.com | 91-22-66322244

# Marico (MRCO IN)

### Rating: ACCUMULATE | CMP: Rs699 | TP: Rs718

### Foods and B2C personal care to drive LT growth

### **Quick Pointers:**

- MRCO targets double-digit revenue growth and strives for double-digit EBITDA growth for FY26, despite near-term cost headwinds
- D2C brands like Beardo and Plix are already profitable and MRCO aims to reach double digit margins in these by FY27.

MRCO managed to deliver double-digit growth in FY25 led by Foods and Premium Personal Care revenue share increasing to ~22% in FY25 (11% in FY11) and double-digit INR sales growth in international business. Innovation funnel remains strong with portfolio diversification and scale up in Foods, D2C portfolio & B2C acquisitions. Beardo has ended FY25 with double-digit EBITDA margins whereas Plix has delivered low single digit EBITDA margin. MRCO plans to adopt the same strategy for scaling Digital-first franchises and targets double-digit margins by FY27. IBD is also focusing on improving mix by reducing reliance on Bangladesh and increasing sales of premium personal care.

Given that copra prices are yet to soften until 1Q26, MRCO has taken another price increase (8-9% in process and 30% overall). We expect margins to remain under pressure until 1HFY26 even as improved profits in Foods and B2C will provide some respite. We increase FY27EPS by 4.5% and estimate a CAGR of 11.9% in sales and 11.5% in EPS over FY25-27. We value MRCO at 47x FY27 EPS and assign a target price of Rs718. Retain Accumulate.

**Sales up 19.8%, Domestic Volume up 7% (Ple:** 6%): Revenues grew by 19.8% YoY to Rs27.3bn (PLe: Rs26.5bn). Domestic Volume Growth 7%: Parachute volumes decline by 1% (PLe:2%). Gross margins contracted by 301bps YoY to 48.6% (Ple: 49.3%). EBITDA grew by 3.6% YoY to Rs4.6bn (PLe:Rs 4.5bn); Margins contracted by 263bps YoY to 16.8% (PLe:17.2%). A&P Spends expanded by 125bps YoY to 11.2%. Adj PAT grew by 7.8% YoY to Rs3.5bn (PLe: Rs3.2bn).

Concall takeaways: 1) Consumer sentiment remained stable amidst improving demand in rural and mixed trends urban markets, however management expects gradual recovery in demand led by moderating inflation and a healthy monsoon season. 2) Copra prices rose 14% sequentially and approximately 48% YoY in FY25, exceeding company expectations, while vegetable oil prices remained firm with a ~25% YoY increase. 3) This pricing cycle has extended beyond the typical 18–24 months, and copra prices are expected to stay elevated in 1QFY26. Consequently, margin pressures are likely to ease after 1HFY26 4) Had A&P spends (+35% YoY in 4Q) grown in line with revenue, EBITDAM would have been 20.3% instead of 19.7% in FY25. 5) Parachute volumes declined 1% due to a sharp rise in consumer pricing and ml-age reduction in select packs, while VAHO saw sequential recovery driven by strong performance in the mid and premium segments. 6) Foods are poised for 25%+ CAGR, supported by scaling existing franchises and continued innovation. Exit ARR for FY27 is now projected at ~2.5x FY24 ARR (up from ~2x earlier). With profitability achieved, MRCO's focus is shifting to strengthening distribution in GT 7) Digital first portfolio clocked ARR of Rs7.5bn on exit basis in FY25. 8) There is significant headroom for TAM expansion in the nutraceuticals space in which Plix operates whereas true elements will see some significant new categories 9) MRCO posted a 16% CCG, with Bangladesh sustained its strong momentum, while Vietnam was muted amidst sluggishness in key category. MENA and SA continue to see traction with high pace growth. 10) While General Trade continues to remain under pressure, Quick commerce continues to be a big growth driver (3% contribution for FMCG whereas 7% contribution for Foods/BPC)

### Exhibit 1: 4QFY25 Results: Revenues up 19.8%, EBITDA margins contracted by 263bps YoY led by higher % of ad spends

Consolidated	4QFY25	4QFY24	YoY gr. (%)	3QFY25	FY25	FY24	YoY gr. (%)
Net Sales	27,300	22,780	19.8	27,940	1,08,310	96,530	12.2
COGS	14,040	11,030	27.3	14,110	53,880	47,480	13.5
% of Net Sales	51.4	48.4	3.0	50.5	49.7	49.2	0.6
Gross Profit	13,260	11,750	12.9	13,830	54,430	49,050	11.0
% of NS	48.6	51.6	-3.0	49.5	50.3	50.8	-0.6
Advt. & Prom.	3,050	2,260	35.0	2,930	11,280	9,520	18.5
% of NS	11.2	9.9	1.3	10.5	10.4	9.9	0.6
Total Expenses	22,720	18,360	23.7	22,610	86,920	76,270	14.0
EBITDA	4,580	4,420	3.6	5,330	21,390	20,260	5.6
Margins (%)	16.8	19.4	-2.6	19.1	19.7	21.0	-1.2
Depreciation	520	410	26.8	440	1,780	1,580	12.7
EBIT	4,060	4,010	1.2	4,890	19,610	18,680	5.0
Interest	120	170	(29.4)	130	530	730	(27.4)
Other Income	470	150	213.3	420	2,080	1,420	46.5
PBT	4,410	3,990	10.5	5,180	21,160	19,370	9.2
Тах	960	790	21.5	1,120	4,580	4,350	5.3
Effective tax rate (%)	21.8	19.8	2.0	21.6	21.6	22.5	-0.8
Adjusted PAT	3,450	3,200	7.8	4,060	16,580	15,020	10.4

Source: Company, PL

### Exhibit 2: Consolidated Segmental: IBD business delivered 16% CCG led by MENA with 47% and SA with 13% growth

(Rs m)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25
Net Sales	22,400	24,770	24,760	24,220	22,780	26,430	26,640	27,940	27,300
Domestic	16,830	18,270	18,320	17,930	16,800	19,620	19,790	21,010	20,680
International	5,570	6,500	6,440	6,290	5,980	6,810	6,850	6,930	6,620
Sales Growth %	3.7	-3.2	-0.8	-1.9	1.7	6.7	7.6	15.4	19.8
Domestic	1.8	-4.9	-3.4	-3.1	-0.2	7.4	8.0	17.2	23.1
International	9.9	2.0	7.3	1.6	7.4	4.8	6.4	10.2	10.7
EBIT	4,200	6,090	5,260	5,360	4,860	6,410	5,670	5,720	4,810
Domestic	3,020	4,280	3,760	3,800	3,390	4,440	3,920	3,920	3,220
International	1,180	1,810	1,500	1,560	1,470	1,970	1,750	1,800	1,590
EBIT Growth %	15.7	9.9	15.4	12.1	15.7	5.3	7.8	6.7	-1.0
Domestic	12.7	7.5	14.3	10.5	12.3	3.7	4.3	3.2	-5.0
International	24.2	16.0	18.1	16.4	24.6	8.8	16.7	15.4	8.2
EBIT Margins %	18.8	24.6	21.2	22.1	21.3	24.3	21.3	20.5	17.6
Domestic	17.9	23.4	20.5	21.2	20.2	22.6	19.8	18.7	15.6
International	21.2	27.8	23.3	24.8	24.6	28.9	25.5	26.0	24.0
Capital Employed	30,920	31,970	35,370	37,540	36,400	39,360	42,470	43,100	38,280
Domestic	22,400	18,740	22,540	24,560	24,260	27,080	29,420	30,800	26,540
International	8,520	13,230	12,830	12,980	12,140	12,280	13,050	12,300	11,740
International Sales Growth %									
Bangladesh (46%)	9.0	9.0	2.0	-6.0	8.0	10.0	8.0	20.0	11.0
MENA (15%)	37.0	15.0	34.0	26.0	19.0	20.0	43.0	35.0	47.0
South Africa (8%)	21.0	37.0	23.0	33.0	13.0	28.0	20.0	17.0	13.0
SE Asia (26%)	16.0	5.0	13.0	4.0	0.0	0.0	7.0	-1.0	-1.0
Source: Company, PL									

### Exhibit 3: Parachute volumes decline 1% YoY




Exhibit 4: Domestic volumes up 7% YoY



Source: Company, PL

Source: Company, PL

### Exhibit 5: Market share remains strong across brands (ex-VAHO)

Market Share (%)	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25
Coconut Oil	62	62	62	62	63	64	63	63	63
Saffola		53	53	53	54	55	54	55	54
Hair Oil VAHO	28	28	27	27	27	27	28	28	28
Livon & Silk and Shine	60	57	55	53	50	49	48	47	47
Hair Creams/Gel	53	53	53	52	52	51	52	52	53
Saffola Oats	43	42	42	41	41	41	41	41	41

Source: Company, PL




Exhibit 6: Cochin/Calicut Copra prices continue to remain firm

2Q19

4Q19 2Q20 4Q20 2021 4021 2022 4022 2Q23

4023 2024 4024 2025

Source: Company, PL

4Q15 2Q16

2Q17


4Q16

2Q18

4Q18

4Q17

4Q25



### Exhibit 7: Movement of key raw material prices wherein Copra prices continue to remain firm


Source: Company, PL


### Exhibit 8: IBD(ex-Vietnam) saw double digit growth in Q4



Source: Company, PL


### Exhibit 9: MRCO's portfolio diversification is on track while GM expansion continues







Supply chain and GTM refinements led to ~1000 bps GM expansion in the last 2 years

### Exhibit 10: Digital First brands are marching ahead with profitable unit economics





Plix delivers low single digit EBITDA margin



## **Financials**

### Income Statement (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
Net Revenues	96,530	1,08,310	1,22,685	1,35,517
YoY gr. (%)	(1.1)	12.2	13.3	10.5
Cost of Goods Sold	47,480	53,880	62,878	68,863
Gross Profit	49,050	54,430	59,807	66,653
Margin (%)	50.8	50.3	48.7	49.2
Employee Cost	7,430	8,310	9,447	10,299
Other Expenses	-	-	-	-
EBITDA	20,260	21,390	23,396	27,062
YoY gr. (%)	11.9	5.6	9.4	15.7
Margin (%)	21.0	19.7	19.1	20.0
Depreciation and Amortization	1,580	1,780	1,891	2,018
EBIT	18,680	19,610	21,505	25,044
Margin (%)	19.4	18.1	17.5	18.5
Net Interest	730	530	579	605
Other Income	1,420	2,080	2,204	2,135
Profit Before Tax	19,370	21,161	23,130	26,574
Margin (%)	20.1	19.5	18.9	19.6
Total Tax	4,350	4,580	5,089	5,979
Effective tax rate (%)	22.5	21.6	22.0	22.5
Profit after tax	15,020	16,581	18,042	20,595
Minority interest	730	740	814	895
Share Profit from Associate	-	-	-	-
Adjusted PAT	14,290	15,841	17,228	19,699
YoY gr. (%)	9.8	10.9	8.8	14.3
Margin (%)	14.8	14.6	14.0	14.5
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	14,290	15,841	17,228	19,699
YoY gr. (%)	9.8	10.9	8.8	14.3
Margin (%)	14.8	14.6	14.0	14.5
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	14,290	15,841	17,228	19,699
Equity Shares O/s (m)	1,290	1,290	1,290	1,290
EPS (Rs)	11.1	12.3	13.4	15.3

Source: Company Data, PL Research

### Balance Sheet Abstract (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
Non-Current Assets				
Gross Block	23,250	24,749	26,249	27,749
Tangibles	13,450	14,702	16,202	17,702
Intangibles	9,800	10,047	10,047	10,047
	-,	,	,	,
Acc: Dep / Amortization	6,730	8,039	9,397	10,867
Tangibles	6,300	7,452	8,659	9,979
Intangibles	430	587	738	888
Net fixed assets	16,520	16,710	16,852	16,882
Tangibles	7,150	7,250	7,543	7,723
Intangibles	9,370	9,460	9,309	9,159
Capital Work In Progress	440	400	500	500
Goodwill	8,630	8,570	8,569	8,569
Non-Current Investments	4,470	2,430	2,458	2,489
Net Deferred tax assets	(2,110)	(1,910)	(2,339)	(2,818)
Other Non-Current Assets	3,440	3,870	4,318	4,902
Current Assets				
Investments	2,590	13,750	12,882	12,197
Inventories	13,360	12,350	14,489	15,834
Trade receivables	10,690	12,710	8,403	8,911
Cash & Bank Balance	9,450	7,790	12,022	13,766
Other Current Assets	3,780	4,130	3,067	3,388
Total Assets	74,210	83,380	84,207	88,041
Equity				
Equity Share Capital	1,290	1,290	1,290	1,290
Other Equity	37,030	38,460	42,108	45,969
Total Networth	38,320	39,750	43,398	47,259
Non Current Liebilities				
Non-Current Liabilities Long Term borrowings	_	_	_	
Provisions	-	-	-	-
	10	10 270	-	-
Other non current liabilities	190	270	297	327
Current Liabilities				
ST Debt / Current of LT Debt	3,830	3,790	3,790	3,790
Trade payables	15,810	13,630	15,524	17,170
Other current liabilities	4,800	7,190	6,128	6,711
Total Equity & Liabilities	74,210	83,380	84,207	88,041

Source: Company Data, PL Research

### Cash Flow (Rs m)

Y/e Mar	FY24	FY25	FY26E	FY27E
РВТ	19,370	21,161	23,130	26,574
Add. Depreciation	1,580	1,780	1,891	2,018
Add. Interest	730	530	579	605
Less Financial Other Income	1,420	2,080	2,204	2,135
Add. Other	2,370	8,680	(3,962)	(2,719)
Op. profit before WC changes	24,050	32,150	21,638	26,479
Net Changes-WC	1,090	(12,250)	4,897	731
Direct tax	(4,350)	(4,580)	(5,089)	(5,979)
Net cash from Op. activities	20,790	15,320	21,446	21,231
Capital expenditures	(6,130)	(2,080)	(2,532)	(2,469)
Interest / Dividend Income	-	-	-	-
Others	1,750	1,280	-	-
Net Cash from Invt. activities	(4,380)	(800)	(2,532)	(2,469)
Issue of share cap. / premium	(600)	(2,066)	(537)	(586)
Debt changes	(920)	(40)	-	-
Dividend paid	(12,290)	(13,545)	(13,566)	(15,827)
Interest paid	(730)	(530)	(579)	(605)
Others	-	-	-	-
Net cash from Fin. activities	(14,540)	(16,180)	(14,682)	(17,018)
Net change in cash	1,870	(1,660)	4,232	1,744
Free Cash Flow	14,660	13,240	18,914	18,762

Key Financial Metrics				
Y/e Mar	FY24	FY25	FY26E	FY27E
Per Share(Rs)				
EPS	11.1	12.3	13.4	15.3
CEPS	12.3	13.7	14.8	16.8
BVPS	29.7	30.8	33.6	36.6
FCF	11.4	10.3	14.7	14.5
DPS	9.5	10.5	10.5	12.3
Return Ratio(%)				
RoCE	44.0	45.8	47.4	51.0
ROIC	30.0	31.7	36.3	40.3
RoE	37.5	40.6	41.4	43.5
Balance Sheet				
Net Debt : Equity (x)	(0.2)	(0.4)	(0.5)	(0.5)
Net Working Capital (Days)	31	39	22	20
Valuation(x)				
PER	63.1	56.9	52.3	45.7
P/B	23.5	22.7	20.8	19.1
P/CEPS	56.8	51.1	47.1	41.5
EV/EBITDA	44.1	41.3	37.6	32.5
EV/Sales	9.2	8.2	7.2	6.5
Dividend Yield (%)	1.4	1.5	1.5	1.8

Source: Company Data, PL Research

Source: Company Data, PL Research

### Quarterly Financials (Rs m)

Y/e Mar	Q1FY25	Q2FY25	Q3FY25	Q4FY25
Net Revenue	26,430	26,640	27,940	27,300
YoY gr. (%)	6.7	7.6	15.4	19.8
Raw Material Expenses	12,620	13,110	14,110	14,040
Gross Profit	13,810	13,530	13,830	13,260
Margin (%)	52.3	50.8	49.5	48.6
EBITDA	6,260	5,220	5,330	4,580
YoY gr. (%)	9.1	5.0	3.9	3.6
Margin (%)	23.7	19.6	19.1	16.8
Depreciation / Depletion	410	410	440	520
EBIT	5,850	4,810	4,890	4,060
Margin (%)	22.1	18.1	17.5	14.9
Net Interest	170	110	130	120
Other Income	370	400	420	470
Profit before Tax	6,050	5,100	5,180	4,410
Margin (%)	22.9	19.1	18.5	16.2
Total Tax	1,310	1,220	1,120	960
Effective tax rate (%)	21.7	23.9	21.6	21.8
Profit after Tax	4,740	3,880	4,060	3,450
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	4,740	3,880	4,060	3,450
YoY gr. (%)	8.7	7.8	5.2	7.8
Margin (%)	17.9	14.6	14.5	12.6
Extra Ord. Income / (Exp)	-	450	-	-
Reported PAT	4,740	4,330	4,060	3,450
YoY gr. (%)	8.7	20.3	5.2	7.8
Margin (%)	17.9	16.3	14.5	12.6
Other Comprehensive Income	(590)	170	(170)	(150)
Total Comprehensive Income	4,150	4,500	3,890	3,300
Avg. Shares O/s (m)	1,291	1,291	1,291	1,291
EPS (Rs)	3.7	3.0	3.1	2.7

7



### Marico

### **Price Chart**



No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	09-Apr-25	Accumulate	672	679
2	31-Jan-25	Accumulate	704	671
3	08-Jan-25	Accumulate	675	638
4	29-Oct-24	Accumulate	693	629
5	07-Oct-24	Hold	681	690
6	05-Aug-24	Hold	681	672
7	09-Jul-24	Accumulate	621	615
8	28-May-24	Accumulate	606	603
9	06-May-24	Accumulate	588	530

**Recommendation History** 

### Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Asian Paints	Reduce	2,094	2,394
2	Avenue Supermarts	Hold	3,942	4,054
3	Britannia Industries	BUY	5,881	5,179
4	Colgate Palmolive	Hold	2,650	2,440
5	Dabur India	Hold	494	459
6	Emami	Accumulate	709	584
7	Hindustan Unilever	Accumulate	2,601	2,325
8	ITC	Accumulate	524	413
9	Jubilant FoodWorks	Hold	678	682
10	Kansai Nerolac Paints	Accumulate	288	258
11	Marico	Accumulate	672	679
12	Metro Brands	Hold	1,162	1,046
13	Mold-tek Packaging	Accumulate	621	470
14	Nestle India	Accumulate	2,559	2,433
15	Pidilite Industries	Accumulate	3,318	2,931
16	Restaurant Brands Asia	Accumulate	74	67
17	Titan Company	BUY	3,695	3,122
18	Westlife Foodworld	Hold	777	706

### PL's Recommendation Nomenclature (Absolute Performance)

Buy Accumulate Hold Reduce Sell Not Rated (NR)	: :	> 15% 5% to 15% +5% to -5% -5% to -15% < -15% No specific call on the stock
Under Review (UR)	:	Rating likely to change shortly



### **ANALYST CERTIFICATION**

### (Indian Clients)

We/I, Mr. Amnish Aggarwal- MBA, CFA, Ms. Hasti Savla- CA, Mr. Vishwa Solanki- PGDM - Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### (US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

### **DISCLAIMER**

### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Amnish Aggarwal- MBA, CFA, Ms. Hasti Savla- CA, Mr. Vishwa Solanki- PGDM - Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

### US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

### Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com